A5077861885- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- TGF-β signaling in diseases
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Cytokine Signaling Pathways and Interactions
- Cancer, Hypoxia, and Metabolism
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Pancreatitis Pathology and Treatment
- Mitochondrial Function and Pathology
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- Sirtuins and Resveratrol in Medicine
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- Cancer Mechanisms and Therapy
- Neuroendocrine Tumor Research Advances
University of Illinois Chicago
2014-2024
Illinois College
2014-2024
Northwestern University
2012-2024
University of Wisconsin–Madison
2024
University of Illinois Urbana-Champaign
2014-2022
University of Illinois Chicago, Rockford campus
2017
Midwestern University
2015
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2015
University of California, Irvine
2014
Inserm
2014
In early pancreatic carcinogenesis, TGFβ acts as a tumor suppressor due to its growth-inhibitory effects in epithelial cells. However, advanced disease, appears promote progression. Therefore, better understand the contributions of signaling we generated mouse models cancer with either or systemic TGFBR deficiency. We found that suppression signals facilitated tumorigenesis, whereas global loss protected against development via inhibition tumor-associated fibrosis, stromal TGFβ1 production,...
Sirtuins participate in sensing nutrient availability and directing metabolic activity to match energy needs with production consumption. However, the pivotal targets for sirtuins cancer are mainly unknown. In this study, we identify M2 isoform of pyruvate kinase (PKM2) as a critical target sirtuin SIRT2 implicated cancer. PKM2 directs synthesis acetyl-CoA, latter which is transported mitochondria use Krebs cycle generate ATP. Enabled by shotgun mass spectrometry analysis founded on tissue...
Abstract Pancreatic ductal adenocarcinoma (PDAC) remains remarkably lethal with a 5-year survival rate of 8%. This is mainly attributed to the late stage presentation, as well widespread resistance conventional therapy. In addition, PDAC tumors are largely nonimmunogenic, and most patients have displayed incomplete responses cancer immunotherapies. Our group has previously identified TGFβ crucial repressor antitumor immune function in PDAC, particularly respect cytotoxic T lymphocytes....
While TGFβ signals are anti-proliferative in benign and well-differentiated pancreatic cells, appears to promote the progression of advanced cancers. To better understand dysregulation pathway, we first generated mouse models neoplastic disease with receptor deficiencies. These displayed reduced levels pERK irrespective KRAS mutation. Furthermore, exogenous led rapid sustained TGFBR1-dependent ERK phosphorylation duct cells. Similar results that our group has published colon cancer...
Pancreatic ductal adenocarcinoma (PDAC) is associated with extensive dysregulation of the epigenome and epigenetic regulators, such as bromodomain extraterminal motif (BET) proteins, have been suggested potential targets for therapy. However, single-agent BET inhibition has shown poor efficacy in clinical trials, no approaches are currently used PDAC. To circumvent limitations current generation inhibitors, we developed compound XP-524 an inhibitor protein BRD4 histone acetyltransferase...
There is currently no effective treatment for pancreatic ductal adenocarcinoma (PDAC). While palliative chemotherapy offers a survival benefit to most patients, nearly all will eventually progress on and long-term survivability remains poor. Given the lack of subsequent line options, in this study, we sought identify novel strategies prevent, delay, or overcome resistance gemcitabine, one widely used medications PDAC. Using combination single-cell RNA sequencing high-throughput proteomic...
// Kyle M. Schachtschneider 1, 2, 3 , Regina Schwind Kwame A. Darfour-Oduro 1 Arun K. De Lauretta Rund Kuldeep Singh 4 Daniel R. Principe 5 Grace Guzman 6 Charles E. Ray Jr. 3, 7 Howard Ozer Ron C. Gaba and Lawrence B. Schook Department of Animal Sciences, University Illinois, Urbana, IL, USA 2 Breeding Genomics Centre, Wageningen University, Wageningen, The Netherlands Radiology, Illinois at Chicago, Veterinary Diagnostic Laboratory, College Medicine, Pathology, Division...
Understanding cell signaling pathways that contribute to metastatic colon cancer is critical risk stratification in the era of personalized therapeutics. Here, we dissect unique involvement mitogenic a TGFβ or activin-induced phenotype cancer. Mitogenic signaling/growth factor receptor status and p21 localization were correlated primary cancers intestinal tumors from either AOM/DSS treated ACVR2A (activin 2) −/− wild type mice. Colon lines (+/− SMAD4) interrogated for ligand-induced PI3K...
Abstract The immune system plays dual roles in response to cancer. host protects against tumor formation via immunosurveillance; however, recognition of the by cells also induces sculpting mechanisms leading a Darwinian selection cell variants with reduced immunogenicity. Cancer immunoediting is concept used describe complex interplay between and system. This concept, commonly referred as three E’s, encompassed 3 distinct phases elimination, equilibrium, escape. Despite impressive results...
Transforming Growth Factor β (TGFβ) is a key mediator of immune evasion in pancreatic ductal adenocarcinoma (PDAC), and the addition TGFβ inhibitors select immunotherapy regimens shows early promise. Though target SMAD4 deleted approximately 55% PDAC tumors, effects loss on tumor immunity have yet to be fully explored. Using combination genomic databases specimens, we found that tumors with comparatively poor T-cell infiltrate. was also associated reduction several chemokines known roles...
Abstract The incidence and mortality of hepatocellular carcinoma (HCC) are on a rise in the Western countries including US, attributed mostly to late detection. Sorafenib has been first-line FDA-approved drug for advanced unresectable HCC almost decade, but with limited efficacy due development resistance. More recently, several other multi-kinase inhibitors (lenvatinib, cabozantinib, regorafenib), human monoclonal antibody (ramucirumab), immune checkpoint (nivolumab, pembrolizumab) have...
<p>Supplemental Figure Legends</p>
<p>Figure S3. KRAS mutation is not associated with additional alterations to tumor immunogenicity</p>